Literature DB >> 32675413

Validity and Reliability of the German Quality of Life-Alzheimer's Disease (QoL-AD) Self-Report Scale.

Vanessa Stypa1, Peter Haussermann1, Tim Fleiner1,2, Sandra Neumann3.   

Abstract

BACKGROUND: The Quality of Life-Alzheimer's Disease (QoL-AD) scale is a widely used measure of quality of life (QoL) in dementia. Although the instrument has been validated in several languages, the psychometric properties of the German self-report version have not yet been analyzed.
OBJECTIVE: This study examines the internal consistency, test-retest reliability, and construct validity of the German QoL-AD self-report scale.
METHODS: The sample included 30 patients suffering from mild to moderate Alzheimer's disease or vascular dementia (19 females; mean age 77.3 years; mean Mini-Mental State Examination (MMSE) score 19.7 points). To determine test-retest reliability, the QoL-AD self-report scale was re-administered four to seven days apart. For construct validity analysis, the Dementia Quality of Life instrument (DQoL), Geriatric Depression Scale (GDS), MMSE, and an adapted short form of the Neuropsychiatric Inventory (NPI) were used.
RESULTS: The German QoL-AD self-report scale shows an internal consistency of α= 0.79 and a test-retest reliability of r = 0.75 (p < 0.01). Regarding construct validity, there was a significant positive correlation between the total scores of the QoL-AD and DQoL (r = 0.47, p < 0.05). The analysis revealed no significant correlations with the GDS or the adapted NPI. No association could be observed between the QoL-AD and the MMSE (r = 0.01), confirming divergent validity.
CONCLUSION: The results indicate that the German QoL-AD self-report scale is a suitable instrument for assessing QoL in patients suffering from mild to moderate dementia, thus supporting its use in clinical practice and research.

Entities:  

Keywords:  Alzheimer’s disease; Germany; dementia; quality of life; reliability and zzm321990validity; self report

Year:  2020        PMID: 32675413     DOI: 10.3233/JAD-200400

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  Curcumin slows the progression of Alzheimer's disease by modulating mitochondrial stress responses via JMJD3-H3K27me3-BDNF axis.

Authors:  Jingna Li; Shanshan Wang; Simiao Zhang; Dan Cheng; Xiaopeng Yang; Yutong Wang; Honglei Yin; Yajun Liu; Yanqiu Liu; Hongying Bai; Shuang Geng; Yunliang Wang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Advanced nursing practice and interprofessional dementia care (InDePendent): study protocol for a multi-center, cluster-randomized, controlled, interventional trial.

Authors:  Fabian Kleinke; Bernhard Michalowsky; Anika Rädke; Moritz Platen; Franka Mühlichen; Annelie Scharf; Wiebke Mohr; Peter Penndorf; Thomas Bahls; Neeltje van den Berg; Wolfgang Hoffmann
Journal:  Trials       Date:  2022-04-11       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.